基質金屬蛋白酶-7促進因子的基因多型性對中台灣腎臟癌的貢獻度
廖丞晞1,2,3,4 張文馨2,3 吳錫金5 蔡佳紋2,3 包大靝2,3,4
1國軍台中總醫院泌尿外科; 2中國醫藥大學生物醫學研究所; 3Terry Fox癌症研究室;
4國防醫學院臨床醫學研究所; 5中國醫藥大學附設醫院泌尿外科
THE CONTRIBUTION OF MATRIX METALLOPROTEINASE-7 PROMOTER POLYMORPHISMS IN RENAL CELL CARCINOMA IN MID-TAIWAN
Cheng-Hsi Liao1,2,3,4 , Wen-Shin Chang2,3 , Hsi-Chin Wu5, Chia-Wen Tsai2,3,and Da-Tian Bau1,2
1 Department of Urology, Taichung Armed Forces General Hospital, Taichung, Taiwan, R.O.C.;
2 Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan, R.O.C.;
3 Terry Fox Cancer Research Laboratory;
4 Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei, Taiwan, R.O.C.;
5 Department of Urology, China Medical University Hospital, Taichung, Taiwan, R.O.C.;
Purpose:
Mounting evidence has suggested that polymorphisms in the promoters of matrix metalloproteinase (MMP) genes are associated with the risk of many types of cancer, but no study has ever explored these polymorphisms as biomarkers for renal cell cancer (RCC). Recently, it was suggested that serum MMP-7 levels have both diagnostic and prognostic potential for RCC. In this study, we focused on the contribution of two functional polymorphisms in the promoter region of MMP-7 (A-181G and C-153T) to RCC.
Materials and Methods:
These two polymorphisms were genotyped in 92 patients with RCC and 580 controls by PRCRFLP analysis.
Results:
The results showed that there is no significant association of the RCC risk with the MMP-7 A-181G genotype, even after adjusted for the possible confounding factors. The MMP-7 C-153T polymorphism was not identified among the subjects investigated.
Conclusions:
Our findings suggest that the two MMP-7 polymorphisms A-181G and C-153T do not play a major role in determining personal susceptibility to RCC in Taiwan.